Sarret Joseph J. Form 3 April 21, 2010

## FORM 3

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting

Person \*

Sarret Joseph J.

(Last)

(First)

(Middle)

Statement

(Month/Day/Year)

04/21/2010

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

CODEXIS INC [CDXS]

4. Relationship of Reporting

(Check all applicable)

CBO, President Pharmaceuticals

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O CODEXIS, INC., 200 PENOBSCOT DRIVE

(Street)

Director \_X\_\_ Officer

Person(s) to Issuer

10% Owner Other (give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

**REDWOOD** CITY, CAÂ 94063

> (City) (State) (Zip)

1. Title of Security

(Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial

Ownership (Instr. 5)

or Indirect (I) (Instr. 5)

Direct (D)

13,333 (1) Common Stock I See Footnote (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

or Exercise Price of Derivative

5. Conversion Ownership Form of Derivative

6. Nature of Indirect Beneficial Ownership (Instr. 5)

Title

Security: Direct (D) Security

Edgar Filing: Sarret Joseph J. - Form 3

	Date	Expiration		Amount or		or Indirect	
	Exercisable	Date		Number of Shares		(I) (Instr. 5)	
Stock Option (right to buy)	(3)	08/11/2015	Common Stock	36,666 <u>(1)</u>	\$ 1.05 <u>(1)</u>	D	Â
Stock Option (right to buy)	(4)	01/26/2017	Common Stock	53,333 (1)	\$ 2.45 (1)	D	Â
Stock Option (right to buy)	(5)	08/28/2017	Common Stock	19,666 <u>(1)</u>	\$ 6.71 <u>(1)</u>	D	Â
Stock Option (right to buy)	(6)	10/25/2017	Common Stock	40,000 (1)	\$ 6.86 (1)	D	Â
Stock Option (right to buy)	(7)	06/02/2019	Common Stock	37,000 (1)	\$ 7.46 <u>(1)</u>	D	Â
Stock Option (right to buy)	(8)	06/02/2019	Common Stock	13,333 (1)	\$ 7.46 <u>(1)</u>	D	Â
Stock Option (right to buy)	(9)	11/09/2019	Common Stock	120,000 (1)	\$ 9.09 (1)	D	Â
Stock Option (right to buy)	(10)	03/11/2020	Common Stock	33,333 (1)	\$ 11.87 <u>(1)</u>	D	Â

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Sarret Joseph J. C/O CODEXIS, INC. 200 PENOBSCOT DRIVE REDWOOD CITY, CA 94063	Â	Â	CBO, President Pharmaceuticals	Â		

# **Signatures**

/s/ Joseph J.
Sarret

\*\*Signature of Reporting Person

O4/21/2010

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects a 2-for-3 reverse stock split of the Issuer's outstanding securities effected immediately prior to the effectiveness of the Issuer's S-1 Registration Statement (Commission File No. 333-164044).
- (2) Shares held by Joseph Sarret as Trustee UTD 5/30/00.
- (3) 100% of the shares subject to the option are fully vested and exercisable.
- Option vests with respect to 25% of the shares subject thereto on January 26, 2008, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on January 26, 2011.

Reporting Owners 2

### Edgar Filing: Sarret Joseph J. - Form 3

- Option vests with respect to 25% of the shares subject thereto on August 28, 2008, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on August 28, 2011.
- Option vests with respect to 25% of the shares subject thereto on October 25, 2008, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on October 25, 2011.
- Option vests with respect to 25% of the shares subject thereto on March 1, 2010, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on March 1, 2013.
- Option vests with respect to 1/24th of the shares subject thereto monthly commencing on January 1, 2011, such that the option will be fully vested and exercisable on January 1, 2013.
- Option vests with respect to 25% of the shares subject thereto on October 16, 2010, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on October 16, 2013.
- Option vests with respect to 100% of the shares subject thereto on January 1, 2015. Upon the completion of the Issuer's initial public (10) offering, the option will vest with respect to 25% of the shares subject thereto on January 1, 2011, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on January 1, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.